Considering the above, a potential therapeutic goal could be to block IL-6 or its receptor in pSS, which would reduce systemic and local inflammation, reduce the activation of B cells and autoantibodies, and thus have a favorable effect on the local inflammatory process and systemic autoimmunity in pSS. Here, IL6 is linked to peeling skin syndrome.